Blood · 2006 · 93 citations · 58 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntigen RecognitionAntitumor T Cell ResponsesCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesT Cell ActivationT Cell BiologyAlloreactive T Cell RegulationAlloreactive T Cell ResponsesDonor T-cell AlloreactivityT Cell - Mediated RejectionT Cell-based ImmunotherapyT-cell Responses To Tumor AntigensT-cell Therapy
In HLA-incompatible hematopoietic stem cell transplantation, alloreactive donor T cells recognizing recipient mismatch HLA cause severe graft-versus-host disease (GVHD). Strategies allowing the selective depletion of alloreactive T cells as well as the enhancement of graft-versus-malignancy immunity would be beneficial. We generated donor CD8 T-cell lines in vitro using allogeneic recipient cells mismatched at a single HLA class I allele or haplotype as stimulators. Recipient cells were obtained from acute myeloid leukemias, renal-cell carcinomas, and CD40L-induced B lymphoblasts. Resulting alloreactive T cells were activated by incubating day 21 T-cell cultures with HLA-mismatch transfected K562 cells or recipient-derived fibroblasts. Selective allodepletion (SAD) was subsequently performed by a newly developed immunomagnetic depletion approach targeting the tumor necrosis factor receptor molecule CD137 (4-1BB). Compared with other activation-induced antigens, CD137 showed a superior performance based on a consistently low baseline expression and a rapid up-regulation following alloantigen stimulation. In 15 different SAD experiments, the frequency of alloreactive CD8 T cells was reduced to a median of 9.5% compared with undepleted control populations. The allodepleted T-cell subsets maintained significant antitumor and antiviral CD8 responses. In vitro expansion of tumor-reactive T cells followed by CD137-mediated SAD might enhance the antitumor efficacy of T-cell allografts with lower risk of inducing GVHD.
58
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
CB Lozzio, BB Lozzio · Blood · 1975 · 2.8K citations
Medicine, Hematology, Oncology +14
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
CB Lozzio, BB Lozzio · Blood · 1975 · 2.3K citations · Full text
Medicine, Hematology, Oncology +14
Mark E. Dudley, John R. Wunderlich, James Chih‐Hsin Yang et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text
Medicine, Immunology, Oncology +17